What A Global Public Health Infrastructure Permanently Maintained Would Look Like

Let's be honest about the current state of global health infrastructure, because the gap between what exists and what is needed is the whole story.

The World Health Organization (WHO). The WHO is the closest thing to a global health authority that exists. It coordinates international health responses, sets norms and standards, and provides technical assistance to member states. Its total biennial budget for 2024-2025 was approximately $6.8 billion — about $3.4 billion per year. For context, the Mayo Clinic alone generates over $16 billion in annual revenue. The WHO's budget for the entire planet is a fraction of what a single American hospital system generates.

Worse, the majority of WHO funding is voluntary and earmarked — meaning donors dictate how the money is spent. The WHO cannot allocate resources based on its own assessment of priorities. It must chase funding from member states and private donors, which makes it politically dependent on the very governments it is supposed to hold accountable.

National CDC equivalents. The United States CDC, the European Centre for Disease Prevention and Control (ECDC), China's CDC, and similar agencies exist in many countries. Some are well-resourced and competent. Many are not. There is no binding mechanism for these agencies to share data, coordinate responses, or hold each other accountable. The International Health Regulations (IHR), revised in 2005, require member states to report certain disease events to the WHO. Compliance is voluntary in practice. Multiple countries delayed or suppressed reporting during COVID-19.

Surveillance systems. Global pathogen surveillance is a patchwork. The Global Influenza Surveillance and Response System (GISRS) monitors flu strains through a network of laboratories. The Global Outbreak Alert and Response Network (GOARN) coordinates response teams. Genomic sequencing capacity has expanded dramatically since COVID-19, but it is still concentrated in wealthy countries. Many countries in Africa and Southeast Asia — precisely the regions where novel pathogens are most likely to emerge — have minimal genomic surveillance.

Vaccine manufacturing. During COVID-19, the world discovered that the capacity to develop a vaccine and the capacity to manufacture billions of doses are entirely different problems. mRNA vaccine technology allowed development in record time, but manufacturing was bottlenecked by facility capacity, supply chain constraints, and intellectual property restrictions. Africa, home to 1.4 billion people, manufactured less than 1% of the vaccines used on the continent during the pandemic.

---

The Independent Panel for Pandemic Preparedness and Response, the G20 High Level Independent Panel on Financing the Global Commons for Pandemic Preparedness and Response, the WHO's own reports, and multiple independent academic assessments converge on a remarkably consistent set of requirements.

1. Global Genomic Surveillance Network. A permanently funded network of laboratories — at least one advanced sequencing facility per region — connected in real time, with mandatory data sharing. When a novel pathogen emerges anywhere, genomic data reaches the global network within days. The technology exists. The GISAID platform demonstrated during COVID-19 that real-time global sharing of genomic data is feasible. What is missing is the permanent infrastructure and the binding data-sharing agreements.

2. Permanent Surge Manufacturing. Regional manufacturing hubs — distributed across continents, not concentrated in a handful of wealthy countries — with maintained production lines that can pivot to pandemic products within weeks. This means paying for idle capacity during non-pandemic periods. That is the cost of readiness. We do it for military hardware. We can do it for vaccines.

The mRNA Vaccine Technology Transfer Hub established in South Africa during COVID-19 was a step in this direction. It needs to be made permanent, replicated across regions, and backed by technology transfer agreements that do not depend on the goodwill of patent holders.

3. Global Health Security Workforce. A trained, deployable force of epidemiologists, contact tracers, logistics specialists, and community health workers. Not formed during a crisis. Maintained continuously, like military reserves. The WHO's Emergency Medical Teams initiative is a start, but it needs ten times the funding and a permanent roster.

4. Binding International Agreements. The current International Health Regulations have no enforcement mechanism. A revised pandemic treaty — which has been under negotiation since 2021 — needs teeth: mandatory reporting timelines with verifiable compliance, pre-negotiated benefit-sharing agreements for pathogen data and medical countermeasures, and consequences for non-compliance.

5. Sustainable Financing. An independent funding mechanism that does not depend on annual budget negotiations in national legislatures. Proposals include a small levy on international financial transactions, mandatory contributions pegged to GDP, or a dedicated international facility capitalized by member states with disbursement authority independent of donor politics.

---

The estimated cost of permanent pandemic preparedness infrastructure: $15 billion per year in additional international investment, plus roughly $10-15 billion per year in domestic investments by individual countries strengthening their own systems. Call it $30 billion per year globally.

The estimated cost of COVID-19: over $16 trillion in economic losses by 2024 estimates, plus over 20 million excess deaths (The Economist's excess mortality model), plus incalculable social, educational, and psychological damage.

The cost-benefit ratio is not close. For every dollar spent on permanent preparedness, the estimated return in prevented pandemic losses is between 10:1 and 100:1, depending on the model and assumptions.

The Global Preparedness Monitoring Board has noted that the world spends approximately $31 billion per day on military expenditure. One day of global military spending would fund a year of pandemic preparedness.

We are not failing to build this infrastructure because we cannot afford it. We are failing because we have not decided to do it. The obstacle is governance, not economics.

---

Pathogens do not carry passports. A virus emerging in a wet market in one country becomes a pandemic on every continent within weeks. The only effective defense is collective: shared surveillance, shared manufacturing, shared distribution, shared governance.

Every attempt to handle pandemic response nationally — hoarding vaccines, restricting exports, competing for supplies — demonstrably fails. During COVID-19, vaccine nationalism meant that wealthy countries had boosters available while healthcare workers in low-income countries could not get a first dose. This was not just immoral. It was epidemiologically stupid. Unvaccinated populations become variant factories. The Delta and Omicron variants emerged in populations with low vaccination coverage and then swept back through vaccinated countries, requiring new boosters and causing new waves of death.

You cannot protect yourself from a pandemic by building a wall around your country. Biology does not work that way. The only thing that works is acting like one species — one immune system, one surveillance network, one response apparatus.

This is Law 1 at its most visceral. We are literally, biologically, epidemiologically one organism. A pathogen in any body is a threat to every body. The infrastructure that protects humanity must be built for humanity, not for nations.

---

1. The Pandemic Budget. Research your country's spending on pandemic preparedness versus military spending. Calculate the ratio. Then calculate what the next pandemic is likely to cost in GDP, lives, and social disruption. Present the numbers side by side. Let them speak for themselves.

2. The Supply Chain Trace. The next time you receive any medical care — a prescription, a vaccination, a diagnostic test — trace the supply chain. Where were the raw materials sourced? Where was the product manufactured? How did it reach your pharmacy? Notice how many borders that chain crosses, and how many points of failure exist.

3. The Accountability Letter. Write a one-page letter to your elected representative making the case for permanent pandemic preparedness funding. Use the cost-benefit numbers. Keep it factual. Send it.

4. The Solidarity Calculation. COVID-19 vaccines cost roughly $2-$20 per dose to manufacture. Calculate what it would cost to vaccinate every person on Earth against the next pandemic pathogen at $10 per dose. Compare that number to the annual revenue of a single pharmaceutical company. Sit with what that comparison tells you about allocation.